Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 5/20 | 0.35 |
| ▸ | MMP9 | P14780 | 4/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 4/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1983588 | 1.00 | TDP1 (0.36) | TDP1GAAMMP2MMP9MMP3 | |
| SCHEMBL6331007 | 0.88 | TDP1 (0.40) | TDP1MMP2MMP9MMP3MMP13 | |
| SCHEMBL1359080 | 0.88 | GAA (0.39) | GAAKDM4EPKM | |
| SCHEMBL6695687 | 0.85 | PDE7A (0.41) | TDP1MMP2MMP9MMP3MMP13 | |
| SCHEMBL6692266 | 0.85 | LMNA (0.40) | TDP1MMP2MMP9MMP3MMP13 | |
| SCHEMBL221916 | 0.82 | MMP2 (0.45) | TDP1MMP2MMP9MMP3MMP13 | |
| SCHEMBL23354908 | 0.81 | MMP2 (0.39) | TDP1MMP2MMP9MMP3MMP13 | |
| SCHEMBL4620466 | 0.81 | TDP1 (0.36) | TDP1MMP2MMP9MMP3MMP13 | |
| SCHEMBL11534423 | 0.81 | MMP2 (0.47) | TDP1MMP2MMP9MMP3MMP13 | |
| SCHEMBL11484713 | 0.81 | MMP2 (0.47) | TDP1MMP2MMP9MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1482930-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-06-29 | — | — | EP | disclosed |
| US-7745637-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070155810-A1 | Peptide Deformylase Inhibitors | GLAXOSMITHKLINE LLC | 2007-07-05 | — | — | US | disclosed |
| EP-1482930-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050124677-A1 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-06-09 | — | — | US | disclosed |
| EP-1482930-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003077913-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155810-A1 | Peptide Deformylase Inhibitors | PDF, PEPD, DPEP1 | TDP1 505/4885GAA 1043/4885MMP2 857/4885 |
| US-20050124677-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | TDP1 505/4885GAA 1043/4885MMP2 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.